Topline data for BNC210 ATTUNE study in PTSD expected 1H’23Ī copy of the full release, including a copy of the ASX Appendix 4C Cashflow Report can be found on the Company's website.įOR FURTHER INFORMATION PLEASE CONTACT: General:.Topline data for BNC210 PREVAIL study in SAD expected YE’22.Announcement of the date of and Notice of the Annual General Meeting/Proxy Form.Release of Full Year (FY2022) Statutory Accounts.Carina also announced that it had submitted its pre-IND application in March of this year and is on track to file an IND application with the FDA in the second half of 2022 Finally, while the Company has sufficient cash runway to complete the ATTUNE and PREVAIL Studies the Company continues to monitor its expenditures while taking several measures to preserve its cash on hand given the current capital markets landscape. Bionomics’ strategic collaboration partner, Carina Biotech (Carina), which licensed BNC101 for the development of Chimeric Antigen Receptor T cell (CAR-T) therapy, announced it had appointed Australian organisation Cell Therapies to undertake Good Manufacturing Processes (GMP) manufacture of its LGR5 CAR-T cells for a first-in-human clinical trial.
market potential for BNC210 as a treatment for PTSD and SAD, the results of which the Company plans to share more details of in the coming quarters. In the ongoing effort to develop a commercial strategy, Bionomics contracted with Bluestar BioAdvisors to gain further insights into the U.S. The Company also continued to manage its Chemistry Manufacturing and Control (“CMC”) and toxicology activities related to development of BNC210 for future planned studies. These efforts included over-seeing the recurring Independent Safety Review Committee meetings for the ATTUNE study and working with the Contract Research Organisation (“CRO”) to maximize the ongoing study enrollments, an effort that has been made increasingly challenged by pandemic restrictions. ♽uring Q4 FY2022 Bionomics continued to closely manage both of its ongoing ATTUNE and PREVAIL clinical studies.
#Dalo tinting st.louis trial
There are 14 clinical sites open and recruitment of trial participants is underway.įor the purpose of ASX Listing Rule 4.7C.3, the Executive Chairman was paid during the Quarter $191,000 in consulting fees and $8,000 for reimbursement of health benefit insurance in accordance with the consulting agreement, and the other Directors were paid during the Quarter $82,000 in directors’ fees. The PREVAIL Study is evaluating two doses of the oral tablet formulation of BNC210 compared to placebo as an acute treatment for SAD in approximately 150 patients in the U.S. There are 25 clinical sites open and recruitment of trial participants is underway. The ATTUNE Study is evaluating the oral tablet formulation of BNC210 compared to placebo in approximately 200 PTSD patients in the U.S.
Wainwright’s Global Investment Conference, 24. Berenberg Capital Markets’ Emerging Biotech Conference,.Citibank Biotech’s Mood Disorders/Mental Health Panel,.On, Bionomics announced that it would be participating in three upcoming investor conferences including:.On 29 April 2022, Bionomics released its Appendix 4C – Quarterly Cashflow Report for the quarter ended 31 March 2022.Errol De Souza, participated in a Fireside Chat hosted by Berenberg Capital Markets analyst Esther Hong to discuss the ongoing BNC210 Phase 2 Social Anxiety Disorder (SAD) PREVAIL, and Post-Traumatic Stress Disorder (PTSD) ATTUNE, trials. On 6 April 2022, Bionomics’ Executive Chairman, Dr.Highlights during the Quarter ended 30 June 2022 (Quarter) and up to the date of this announcement include: ADELAIDE, Australia, J(GLOBE NEWSWIRE) - Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a global, clinical stage biopharmaceutical company, today released its Quarterly Activities and ASX Appendix 4C Cashflow Reports.
0 kommentar(er)
